Deals this week: PaxVax, Qualcomm Incorporated, Sichuan Kelun Pharmaceuticals

1st September 2016 (Last Updated September 1st, 2016 18:30)

PaxVax Inc and Seqirus Inc have entered a marketing and distribution agreement.

PaxVax Inc and Seqirus Inc have entered a marketing and distribution agreement.

Pursuant to the agreement, PaxVax will be responsible to sell and market Agrippal and Fluad, influenza vaccine products of Seqirus, in Switzerland.

The agreement enables PaxVax to expand its vaccines portfolio and Seqirus to market its products in Switzerland.

Qualcomm Incorporated and Boehringer lngelheim Pharmaceuticals have signed a collaboration agreement to jointly improve chronic obstructive pulmonary disease (COPD) care.

Pursuant to the agreement, the two partners will develop a connectivity solution for the latter’s Respimat inhaler to develop respiratory therapies.

The transaction enables the partners to develop new digital technology-based Respimat inhaler.

Sichuan Kelun Pharmaceuticals plans to issue bonds due 2021 in a public offering. The company expects to raise gross proceeds of $296.5m through the offering.

"Xiangxue Pharmaceutical Co Ltd has raised gross proceeds of $112.3m through the public offering of first tranche super short-term financing notes."

Xiangxue Pharmaceutical Co Ltd has raised gross proceeds of $112.3m through the public offering of first tranche super short-term financing notes.

China Minsheng Banking Corp has acted as book runner and underwriter to the offering.

Gansu Longshenrongfa Pharmaceutical plans to offer 2.1m common stock shares in an initial public offering.

The company expects to raise gross proceeds of approximately $44.25m from the offering.


Image: Qualcomm is headquartered in San Diego, US. Photo: Courtesy of Coolcaesar.